The CGM datasets obtained by using CGMS® Gold™ (Medtronic®, USA), collected from clinical treatment, are used to evaluate the proposed program. All CGM datasets were provided by the Third Affiliated Hospital of Southern Medical University. Only complete 24-hour CGM data were selected for comparison study. All patients have provided their written informed consent. 5 CGM recordings from 3 T1D patients, 116 CGM measurements contributed by 58 T2D patients, and 127 CGM measurements based on gestational diabetes patients have been collected. Outpatients had been treated with either diet, oral hypoglycemic agents, oral hypoglycemic agents plus insulin, or insulin alone, depending on their glycemic control.
Cgms gold
Manufactured by Medtronic
Sourced in United States
The CGMS Gold is a continuous glucose monitoring system developed by Medtronic. It is designed to continuously measure and record glucose levels in the body. The device includes a sensor that is inserted under the skin to measure glucose levels, and a transmitter that sends the data to a monitoring device. The CGMS Gold provides real-time glucose readings, allowing users to track their glucose levels throughout the day.
Automatically generated - may contain errors
10 protocols using cgms gold
1
Continuous Glucose Monitoring for Diabetes
2
Continuous Glucose Monitoring in Interstitial Fluid
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CGMS® Gold (Medtronic MiniMed, Northridge, CA, USA) was administered for CGM in this study. The glucose sensor was inserted into the subcutaneous tissue of the abdomen of all participants at 08:00–09:00 in the morning to monitor the glucose levels in the interstitial fluid for at least 72 h. Finger stick blood glucose levels were checked to calibrate and four calibrations per day (before meals and at bedtime) were conducted with an Accu-Chek Integra Blood Glucose Meter (Roche) during the CGM period. The subjects returned to our hospital to download the data from CGMS after 3 days. The data analysed using the Solution Software v3.0c.
3
Continuous Glucose Monitoring in Hospitalized Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A CGM system (CGMS Gold; Medtronic Inc., Northridge, CA) was used for subcutaneous interstitial glucose monitoring, as previously described (10 (link)). In brief, the sensor of the CGM system was inserted on the first day during hospital admission (day 0) and removed after 72 h, generating a daily record of 288 continuous sensor values. At least four capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA) to calibrate the CGM system. TIR was defined as the percentage of time in the target glucose range of 3.9–10.0 mmol/L during a 24-h period. In addition, mean glucose and glucose coefficient of variation were calculated. During the 3-day CGM period, all participants adhered to a standard diet designed to ensure a total daily caloric intake of 25 kcal/kg/day, with 55% of calories coming from carbohydrates, 17% from proteins, and 28% from fats, as previously reported (10 (link)).
4
Continuous Glucose Monitoring and Glycemic Metrics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Blood glucose levels were measured for two consecutive days by CGM (CGMS-gold; Medtronic Minimed, Northridge, CA, USA) with SMBG using portable blood glucose meters (One Touch UltraVue; Johnson & Johnson, Tokyo, Japan). We evaluated the 8-hour glucose AUC using MIET and CGM. Moreover, we evaluated several CGM-related parameters [9 ]. Mean glucose levels, standard deviations (SDs) and coefficient of variation (CV) were calculated for all glucose data for 8 hours [9 ]. The mean amplitude of glucose excursion (MAGE) was calculated as the arithmetic mean of the differences between consecutive blood glucose peaks and nadirs provided that the differences are greater than one SD of the mean glucose value. M value was calculated with following formula: ∑ |10×log (blood glucose/100)|3/n, and the J index was calculated as follows: 0.001 (mean blood glucose+SD)2 [15 (link)16 (link)17 (link)].
5
Continuous Glucose Monitoring in Standardized Diet
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A blinded CGM system (CGMS GOLD, Medtronic Inc, Northridge, CA, USA) was used for subcutaneous interstitial glucose monitoring. The sensor of the CGM system was inserted on the first day during hospital admission and removed after 72 h, generating a daily record of 288 continuous sensor values. At least 4 capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. Glucose coefficient of variation (CV) was calculated as the measure of GV. Time in range (TIR) was defined as the percentage of time in the target glucose range of 3.9 to 10.0 mmol/L during a 24-h period. Time above ranges [TARs; TAR > 140 mg/dL (TAR>140), TAR > 180 mg/dL (TAR>180), and TAR > 250 mg/dL (TAR>250)], and time below ranges [TBRs; TBR < 54 mg/dL (TBR<54), and TBR < 70 mg/dL (TBR<70)] were also ascertained. During the CGM period, all participants adhered to a standard diet, as previously reported (14 (link)).
6
Glycemic Control and Sleep Apnea
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
HbA1c level was measured by HPLC. OSA was diagnosed by overnight PSG (for ≥6 h) at our hospital, apnea was defined as the termination of respiratory airflow for ≥10 s, and hypopnea was defined as a ≥50% decrease in ventilation accompanied by a ≥3% decrease in oxygen saturation. AHI was defined as the number of instances of apnea and hypopnea per 1 h (while sleeping). CPAP therapy was introduced in patients with OSA, defined as AHI ≥ 20. Rapid eye movement (REM) AHI, AHI, minimum peripheral capillary oxygen saturation (SpO 2 ), mean SpO 2 , total sleep time (TST), percentage of total sleep time (%TST) with SpO 2 < 90% and REM/TST were also evaluated using PSG. CGM was performed using a CGMS Gold (Medtronic Minimed, Northridge, CA, USA). Patients checked their capillary blood glucose with a Medisafe Fit Pro blood glucose meter (Terumo Corporation, Tokyo, Japan) at least 4 times a day (premeal and bedtime) and entered the readings into the CGM monitor for calibration. After downloading the CGM data, mean glucose and standard deviation (SD) as well as coefficient of variation (CV) of glucose levels were evaluated during a 24 h period between day 2 and day 3. Fasting capillary blood glucose (FBG) was calculated as the mean of day 2 and day 3 measurements.
7
Continuous Glucose Monitoring Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CGM was performed using the CGMS-Gold® device manufactured by Medtronic Inc. A 5-10-min delay occurs with CGMS Gold in the glucose measurement as it involves the use of interstitial fluid, compared with methods involving the use of venous whole blood. It is also reported to be less accurate in glucose measurement during hypoglycemia [18] . The interstitial glucose values obtained with CGMS Gold were adjusted using self-monitored blood glucose values collected four times a day via finger prick and using a handheld glucometer. Blood glucose values indicated by CGMS Gold were virtually identical to the venous values [19] .
8
Diabetes Monitoring using Continuous Glucose Monitoring
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Twenty inpatients with diabetes undergoing CGM (CGMS-Gold; Medtronic, Minneapolis, MN, USA) for the purpose of treatment response monitoring were enrolled. The baseline clinical characteristics of the patients are shown in Table 1 . The study was conducted following the latest version of the Declaration of Helsinki and the study protocol was approved by the Ethics Committee of Shiga University of Medical Science (Shiga, Japan), and all participants provided written informed consent for study participation.
9
Continuous Glucose Monitoring Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A retrospective CGM system (CGMS GOLD; Medtronic Inc., Northridge, CA, USA) was used for glucose monitoring, as previously described.[8 (link)] In brief, the sensor of the CGM system was inserted on day 0 and removed after 72 h, generating a daily record of 288 continuous sensor values. At least four capillary blood glucose readings per day were measured by a SureStep blood glucose meter (LifeScan, Milpitas, CA, USA) to calibrate the CGM system. TIR was defined as the average percentage of time in the target glucose range of 70 to 180 mg/dL (3.9–10.0 mmol/L) during a 24 h period. TAR was defined as the average percentage of time above the target glucose range of 180 mg/dL (10.0 mmol/L). TBR was defined as the average percentage of time below the target glucose range of 70 mg/dL (3.9 mmol/L).
10
Continuous Glucose Monitoring Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CGM was performed using a CGMS Gold (Medtronic Minimed, Northridge, CA, USA). The mean blood glucose level, standard deviation (SD), MAGE, percentage of time with glucose levels of <70, ≥140, and ≥200 mg/dl were measured from the data recorded through CGM using self-monitoring blood glucose (SMBG) device. MAGE, which was proposed by Service et al. [12] , represents fluctuations in blood glucose levels over a 24-hour period and was calculated from the daily variations in blood glucose level, which was measured continuously by CGM over a period of 2 days. Previous studies indicated interstitial glucose concentrations measured by CGM correlate with venous blood glucose levels [13] . CGM measurements represent glucose concentrations in the interstitial fluid, but since the introduction of the SMBG technique, the measured value is considered to represent blood glucose level. SMBG was performed using a ONE TOUCH ULTRA VIEW (Johnson & Johnson K.K, Tokyo, Japan).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!